UBS Sees More Challenges for Merck KGaA in 2027
Merck KGaA raised its full-year guidance again, while UBS analysts see a more challenging 2027 outlook, citing accelerating generic competition for Mavenclad and potential competition for Ogsiveo.
Merck KGaA raised its full-year guidance again, while UBS analysts see a more challenging 2027 outlook, citing accelerating generic competition for Mavenclad and potential competition for Ogsiveo.